NMTC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NMTC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, NeuroOne Medical Technologies's Future 3-5Y Total Revenue Growth Rate is N/A.
For the Medical Devices subindustry, NeuroOne Medical Technologies's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's Future 3-5Y Total Revenue Growth Rate falls into.
NeuroOne Medical Technologies (NAS:NMTC) Future 3-5Y Total Revenue Growth Rate Explanation
Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark Christianson | 10 percent owner, officer: VP, Business Dev and Marketing | 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
Ronald W. Mcclurg | officer: Chief Financial Officer | C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344 |
David A Rosa | director, officer: CEO and President | 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343 |
Hijaz Haris | officer: VP of Marketing | C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344 |
Morgan C. Frank | 10 percent owner | 2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907 |
Manchester Management Co Llc | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02110 |
Manchester Explorer, L.p. | 10 percent owner | MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114 |
James E Besser | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Manchester Management Pr, Llc | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Edward Andrle | director | C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344 |
Wade Fredrickson | 10 percent owner | 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
Steve Mertens | officer: Chief Technology Officer | 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343 |
Scott Heuler | officer: Vice President of Sales | 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343 |
Paul Buckman | director | 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402 |
Suraj Kalia | director | 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
From GuruFocus
By GuruFocus News • 11-15-2024
By Marketwired • 03-18-2025
By Marketwired • 12-04-2024
By GuruFocus News • 01-13-2025
By GuruFocus Research • 08-15-2024
By Marketwired • 01-06-2025
By Marketwired • 09-05-2024
By Marketwired • 02-04-2025
By Marketwired • 09-24-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.